Stock Track | Mabwell Bio Soars 6.44% Intraday on Strong Q1 Revenue Growth and Stock Connect Inclusion

Stock Track
04/30

Mabwell Bio's stock price surged 6.44% during intraday trading on Thursday, marking a significant rebound in its share price.

The sharp rise appears to be driven by the company's recently reported first-quarter financial results, which showed revenue skyrocketing 184.89% year-over-year to RMB 128 million, while net losses narrowed by 17.07%. Additionally, the stock's recent inclusion in the Stock Connect program following its H-share listing has enhanced liquidity by enabling direct participation from mainland investors.

Market attention is also focused on the company's pipeline of ADC and TCE-based oncology therapies, with Phase III interim analyses for its lead candidate expected this year, contributing to positive investor sentiment.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10